References
- Durzyńska J, Goździcka-Józefiak A. Viruses and cells intertwined since the Dawn of evolution. Virol J. 2015;12(1):1.
- De Chassey B, Meyniel-Schicklin L, Aublin-Gex A, et al. New horizons for antiviral drug discovery from virus–host protein interaction networks. Curr Opin Virol. 2012;2(5):606–613.
- Yang X, Lian X, Fu C, et al. HVIDB: a comprehensive database for human–virus protein–protein interactions. Brief Bioinform. 2021;22(2):832–844.
- Gordon DE, Jang GM, Bouhaddou M, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020;583(7816):459–468.
- Sadegh S, Matschinske J, Blumenthal DB, et al. Exploring the SARS-CoV-2 virus-host-drug interactome for drug repurposing. Nat Commun. 2020;11(1):1–9.
- Kory P, Meduri GU, Varon J, et al. Review of the emerging evidence demonstrating the efficacy of ivermectin in the prophylaxis and treatment of COVID-19. Am J Ther. 2021;28(3):e299–318.
- Lopez CE, Legge KL. Influenza A virus vaccination: immunity, protection, and recent advances toward a universal vaccine. Vaccines (Basel). 2020;8(3):434.
- Lee S, Nguyen MT, Currier MG, et al. A polyvalent inactivated rhinovirus vaccine is broadly immunogenic in rhesus macaques. Nat Commun. 2016;7(1):1–7.
- Lee JY, Chang J. Universal vaccine against respiratory syncytial virus A and B subtypes. PLoS One. 2017;12(4):e0175384.
- Wang X, Ku Z, Dai W, et al. A bivalent virus-like particle -based vaccine induces a balanced antibody response against both enterovirus 71 and norovirus in mice. Vaccine. 2015;33(43):5779–5785.
- Goldman GS, King PG. Review of the United States universal varicella vaccination program: herpes zoster incidence rates, cost-effectiveness, and vaccine efficacy based primarily on the Antelope Valley Varicella Active Surveillance project data. Vaccine. 2013;31(13):1680–1694.
- GOSTAR [Internet]. [cited 2021 Aug 18]. Available from: https://www.gostardb.com/gostar/
- Giurgea LT, Han A, Memoli MJ. Universal coronavirus vaccines: the time to start is now. NPJ Vaccines. 2020;5(1):1–3.
- Abrescia NG, Bamford DH, Grimes JM, et al. Structure unifies the viral universe. Annu Revi Biochem. 2012;81:795–822.
- Cornejo-Giraldo M, Rosado N, Salinas J, et al. Tenofovir-DF versus hydroxychloroquine in the treatment of hospitalized patients with COVID-19: an observational study (THEDICOV). medRxiv 2021 Jan 1.
- Yan VC, Muller FL. Advantages of the parent nucleoside GS-441524 over remdesivir for Covid-19 treatment. ACS Med Chem Lett. 2020;11(7):1361–1366.
- Sharun K, Tiwari R, Dhama K. Protease inhibitor GC376 for COVID-19: lessons learned from feline infectious peritonitis. Ann Med Surg. 2021;61:122–125.
- Wu ZQ, Zhang Y, Zhao N, et al. Comparative epidemiology of human fatal infections with novel, high (H5N6 and H5N1) and low (H7N9 and H9N2) pathogenicity avian influenza A viruses. Int J Environ Res Public Health. 2017;14(3):263.
- Shariff M. Nipah virus infection: a review. Epidemiol Infect. 2019;147.
- Heikkinen T, Järvinen A. The common cold. Lancet. 2003;361(9351):51–59.
- Louie JK, Yagi S, Nelson FA, et al. Rhinovirus outbreak in a long-term care facility for elderly persons associated with unusually high mortality. Clinl Infect Dis. 2005;41(2):262–265.